Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherSpecial Contribution

Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden

Sally F. Barrington and Michel A. Meignan
Journal of Nuclear Medicine April 2019, jnumed.119.227249; DOI: https://doi.org/10.2967/jnumed.119.227249
Sally F. Barrington
1 Kings College London, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel A. Meignan
2 LYSA-IM, Hospital Henri Mondor, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Increased tumour burden is associated with inferior outcomes in many lymphoma subtypes. Surrogates of tumour burden that are easy to measure, such as the maximum tumour dimension of the ‘bulkiest’ lesion on CT have been used as prognostic indices for many years. Recently, the total metabolically (active) tumour volume (M(A)TV) and tumour lesion glycolysis (TLG) have emerged as promising and robust biomarkers of outcome in various lymphomas. The median MTV value and the optimal cut-off points to separate patients into risk groups in a study population are however, highly dependent on the population characteristics and the delineation method used to outline tumour in the PET image. This has precluded the use of MTV for risk stratification in trials and clinical practice. Standardisation of the methodology is timely to allow the potential for risk adaptation to be explored in addition to response adaptation using PET. Meetings between representatives from research groups active in the field were held under the auspices of the PET international lymphoma and myeloma workshop. A summary of those discussions, which included a review of the literature and a practical assessment of methods used for outlining, including various software options is presented. Finally, a proposal is made to perform a technical validation of MTV measurement enabling benchmark reference ranges to be derived for published delineation approaches used for outlining with various softwares. This process would require i) collation of representative imaging datasets of the most common lymphoma subtypes, ii) agreement on pragmatic criteria for the selection of lesions, iii) generating a range of MTV values with consensus to be reached on final contours in a training set, and iv) developing automated software solutions with a set of minimum functionalities to reduce measurement variability. Methods developed in the above training exercise could then be applied to another dataset with a final set of contours and values generated. This final dataset would provide a benchmark against which end-users could test their ability to measure MTV consistent with expected values. The dataset and automated software solutions could be shared with manufacturers with the aim to include these in standard workflows to allow standardisation of MTV measurement across the world.

  • Oncology: Lymphoma
  • PET
  • Research Methods
  • lymphoma
  • positron emission tomography
  • standardization
  • Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (5)
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden
Sally F. Barrington, Michel A. Meignan
Journal of Nuclear Medicine Apr 2019, jnumed.119.227249; DOI: 10.2967/jnumed.119.227249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Time to prepare for risk adaptation in lymphoma by standardising measurement of metabolic tumour burden
Sally F. Barrington, Michel A. Meignan
Journal of Nuclear Medicine Apr 2019, jnumed.119.227249; DOI: 10.2967/jnumed.119.227249
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • In Search of Platinum Meter Bar for Measurement of Metabolic Tumor Volume in Lymphoma
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • Oncology: Lymphoma
  • PET
  • research methods
  • lymphoma
  • Positron Emission Tomography
  • standardization
SNMMI

© 2025 SNMMI

Powered by HighWire